Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 904-908

  Wang, Rong ^a   Gross, Cary P ^a,b   Maggiore, Ronald J ^a,b   Halene, Stephanie ^b   Soulos, Pamela R ^a   Raza, Azra ^c   Galili, Naomi ^c   Ma, Xiaomei ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

Chemotherapy; Hematology medical; Myelodysplastic syndromes; New agents

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE;

AGED; ARTICLE; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; POPULATION RESEARCH; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79958721648     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.10.007     Document Type: Article

References (41)

1. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
2. Ma X., Does M., Raza A., Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1536-1542.
3. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
4. Sierra J., Perez W.S., Rozman C., Carreras E., Klein J.P., Rizzo J.D., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002, 100:1997-2004.
5. Hellstrom-Lindberg E., Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol 2008, 45:14-22.
6. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol 2008, 20:705-710.
7. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
8. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
9. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
10. Steensma D.P., Baer M.R., Slack J.L., Buckstein R., Godley L.A., Garcia-Manero G., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009, 27:3842-3848.
11. Kornblith A.B., Herndon J.E., Silverman L.R., Demakos E.P., Odchimar-Reissig R., Holland J.F., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002, 20:2441-2452.
12. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Gattermann N., Germing U., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
13. Mitchell J.M., Meehan K.R., Kong J., Schulman K.A. Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. J Clin Oncol 1997, 15:2644-2651.
14. Roetzheim R.G., Gonzalez E.C., Ferrante J.M., Pal N., Van Durme D.J., Krischer J.P. Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer 2000, 89:2202-2213.
15. Earle C.C., Neumann P.J., Gelber R.D., Weinstein M.C., Weeks J.C. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002, 20:1786-1792.
16. Harlan L.C., Greene A.L., Clegg L.X., Mooney M., Stevens J.L., Brown M.L. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol 2005, 23:9079-9088.
17. Richardson L.C., Tian L., Voti L., Hartzema A.G., Reis I., Fleming L.E., et al. The roles of teaching hospitals, insurance status, and race/ethnicity in receipt of adjuvant therapy for regional-stage breast cancer in Florida. Am J Publ Health 2006, 96:160-166.
18. Ward E., Halpern M., Schrag N., Cokkinides V., DeSantis C., Bandi P., et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008, 58:9-31.
19. Gold H.T., Thwin S.S., Buist D.S., Field T.S., Wei F., Yood M.U., et al. Delayed radiotherapy for breast cancer patients in integrated delivery systems. Am J Manage Care 2009, 15:785-789.
20. Lang K., Marciniak M.D., Faries D., Stokes M., Buesching D., Earle C., et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer 2009, 63:264-270.
21. Shih Y.C., Elting L.S., Halpern M.T. Factors associated with immunotherapy use among newly diagnosed cancer patients. Med Care 2009, 47:948-958.
22. Warren J.L., Klabunde C.N., Schrag D., Bach P.B., Riley G.F. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40:IV-3-IV-18.
23. Lamont E.B., Lauderdale D.S., Schilsky R.L., Christakis N.A. Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care 2002, 40:201-211.
24. Lamont E.B., Herndon J.E., Weeks J.C., Henderson I.C., Lilenbaum R., Schilsky R.L., et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst 2005, 97:1080-1083.
25. International classification of diseases for oncology 2000, World Health Organization. 3rd ed. A. Fritz (Ed.).
26. Anderson L.A., Pfeiffer R.M., Landgren O., Gadalla S., Berndt S.I., Engels E.A. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009, 100:822-828.
27. Anderson L.A., Pfeiffer R., Warren J.L., Landgren O., Gadalla S., Berndt S.I., et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 2008, 17:3069-3075.
28. Ma X., Lim U., Park Y., Mayne S.T., Wang R., Hartge P., et al. Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am J Epidemiol 2009, 169:1492-1499.
29. Wang R., Gross C.P., Halene S., Ma X. Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States. Cancer Causes Control 2009, 20:1369-1376.
30. Wang R., Gross C.P., Halene S., Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 2009, 33:1594-1598.
31. Piccirillo J.F., Spitznagel E.L., Vermani N., Costas I., Schnitzler M. Comparison of comorbidity indices for patients with head and neck cancer. Med Care 2004, 42:482-486.
32. Sharma G., Freeman J., Zhang D., Goodwin J.S. Trends in end-of-life ICU use among older adults with advanced lung cancer. Chest 2008, 133:72-78.
33. Wong Y.N., Mitra N., Hudes G., Localio R., Schwartz J.S., Wan F., et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683-2693.
34. Elixhauser A., Steiner C., Harris D.R., Coffey R.M. Comorbidity measures for use with administrative data. Med Care 1998, 36:8-27.
35. Quan H., Sundararajan V., Halfon P., Fong A., Burnand B., Luthi J.C., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43:1130-1139.
36. Bach P.B., Guadagnoli E., Schrag D., Schussler N., Warren J.L. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 2002, 40:IV-19-IV-25.
37. Sekeres M.A., Schoonen W.M., Kantarjian H., List A., Fryzek J., Paquette R., et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008, 100:1542-1551.
38. Hatoum H.T., Lin S.-J., Buchner D., Kim E. Patterns of hypomethylating agent and transfusion use in myelodysplastic syndrome: a claims database study. ASH Annual Meeting Abstracts, vol. 114 2009, p. 2490.
39. Van Bennekom C, Abel G, Anderson T, Stone R, Kaufman D. Patterns of treatment among patients with recently-diagnosed myelodysplastic syndromes in a national registry, 2006-2008. American Society of Hematology Annual Meeting. San Francisco: Blood; 2008.
40. Steensma D.P., Stone R.M. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am 2010, 24:389-406.
41. Deschler B., de Witte T., Mertelsmann R., Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006, 91:1513-1522.